Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week

Journal Scan / Research · December 09, 2020

Treatment of High-Grade Non–Muscle-Invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations vs Reduced Number and Standard Dose of BCG Instillations

European Urology

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Urology
Treatment of High-Grade Non–Muscle-Invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS"
Eur Urol 2020 May 20;[EPub Ahead of Print], MO Grimm, AG van der Heijden, M Colombel, T Muilwijk, L Martínez-Piñeiro, MM Babjuk, LN Türkeri, J Palou, A Patel, AS Bjartell, C Caris, RG Schipper, WPJ Witjes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading